Icon Plc

Icon Plc

ICLR

Get informed when a big investor buys or sells

+ Follow
Market Cap$12.84B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Icon PlcIcon Plc29.6-2%1.50.5

Earnings Call Q3 2024

October 24, 2024 - AI Summary

**Q3 Performance and Revised Guidance**: ICON's Q3 results were below expectations, with revenue of $2.03 billion, a year-on-year decrease of 1.2% (1% on a constant currency basis). Due to challenges primarily impacting two large customers and the biotech segment, the company provided a full-year revenue growth guidance of low to mid-single digits for 2024, significantly revised from previous expectations.
**Key Challenges Identified**: Three main challenges reduced revenue expectations: 1. Continued cost pressures on two top customers leading to tighter development spending and delays in project ramp-up. 2. Slower decision-making and capital allocation within the biotech sector, causing award delays and slow trial starts. 3. An outsized number of project cancellations in the vaccine sector, contributing to lower expected revenue.
**Healthy Backlog and Business Development**: Despite the challenges, ICON achieved gross business wins of $2.832 billion (down 7.3% YoY) with a backlog growth to $24.3 billion (up 9.4% YoY). This growth indicates robust future revenue potential from new awards, including a focus on strengthening partnerships in areas like cardiovascular and metabolic diseases.

Exclusive for Stockcircle Pro members

Sign upSign Up
$160.13

Target Price by Analysts

3.6% downsideIcon Plc Target Price DetailsTarget Price
$167.36

Current Fair Value

0.8% upside

Undervalued by 0.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$12.84 Billion
Enterprise Value$17.16 Billion
Dividend Yield$- (-)
Earnings per Share$2.92
Beta1.22
Outstanding Shares76,579,420

Return

Return on Equity1.93%ROE
Return on Assets1.10%
Return on Invested Capital2.99%

Valuation & Multiples

P/E Ratio29.63P/E Ratio
PEG-92.46PEG
Price to Sales1.54Price to Sales
Price to Book Ratio1.37Price to Book Ratio
Enterprise Value to Revenue2.07
Enterprise Value to EBIT43.67
Enterprise Value to Net Income95
Total Debt to Enterprise0.3
Debt to Equity0.55Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
June 23, 2026
EPS Estimate
$2.43
Average shareholder expectation
Revenue Estimate
$2.00 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 22, 2026
EPS Estimate
$2.57
Average shareholder expectation
Revenue Estimate
$1.98 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 61.38%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %2.32%▼ 98.65%
Total Invested$309.00M▼ 96.47%
Investors Holding19▼ 421.00%

ESG Score

No data

About Icon Plc

CEO: Stephen Cutler

Relevant Senate Committees

Joint Committee on Taxation

As the expert body providing official revenue estimates for all tax bills, its technical expertise and reports directly influence corporate tax structures and capital investment credits, critically affecting Icon Plc's financial planning and operational costs.

Finance

This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy (e.g., R&D credits) and Medicare pricing directly impact the financial health and market potential of Icon Plc's pharmaceutical clients.

Appropriations

This committee allocates discretionary federal spending, and its subcommittees directly determine the precise funding for scientific research programs (e.g., NIH, CDC), which directly affects the volume and types of research projects Icon Plc conducts.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA and NIH, which are central to drug approval processes and research funding, making it highly influential over the pharmaceutical and biotech sectors, directly impacting Icon Plc's business.

Judiciary

This committee's jurisdiction over intellectual property laws is critical for biotechnology and drug development, and its role in antitrust oversight can influence mergers in the pharma industry, impacting Icon Plc's client base and competitive landscape.

Select Committee on Intelligence

Members receive classified briefings on global threats, including potential biological threats or health crises, which can directly drive R&D funding and priorities in the biotech sector, creating high informational asymmetry relevant to Icon Plc.